Vistagen Therapeutics, Inc. (VTGN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US92840H4002
Vistagen Therapeutics, Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 486,000.00 USD | 1.27 m USD |
| Operating income | -55.97 m USD | -72.13 m USD |
| EBIT | -51.41 m USD | -69.68 m USD |
| Net income | -51.42 m USD | -69.69 m USD |
| Diluted EPS – continuing operations | -1.67 USD | -1.83 USD |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
More stocks
- ACCURAY INC (ARAY)
- INNOVATIVE DESIGNS INC (IVDN)
- GREENLITE VENTURES INC (GRNL)
- Moleculin Biotech, Inc. (MBRX)
- Upland Software, Inc. (UPLD)
- CalciMedica, Inc. (CALC)
- Summit Networks Inc. (SNTW)
- INTRUSION INC (INTZ)
- Reborn Coffee, Inc. (REBN)
- Cardlytics, Inc. (CDLX)
- VPR Brands, LP. (VPRB)
- Ensysce Biosciences, Inc. (ENSC)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.